Articles from Argonaut Manufacturing Services

Today, Argonaut Manufacturing Services (“Argonaut”), a US-based sterile fill-finish CDMO, and Ensera, a CDMO with facilities in the US, and Europe and Asia, specializing in final assembly and secondary packaging for drug delivery systems, announce a new strategic partnership.

The Vallabh/Minikel lab at the Broad Institute has selected Argonaut Manufacturing Services, Inc., “Argonaut,” as the drug product manufacturer for a therapeutic compound for a potential clinical trial for prion disease.

Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced today that Argonaut will act as the manufacturing partner for Akoya’s IVD assays currently in development. This agreement builds on years of collaboration between Argonaut and Akoya, reflecting Argonaut’s proven ability to support both emerging and mature diagnostic product lines. Furthermore, this expanded collaboration underscores both companies’ commitment to advancing precision medicine through high-quality diagnostics.

Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45 million financing to support its new drug product fill / finish expansion. This expansion in Carlsbad, CA, underway since early 2023, includes a new dedicated facility with a state-of-the-art isolator-based filling line that more than quadruples Argonaut’s existing drug product fill / finish capacity and augments existing vial filling capabilities with the ability to pre-fill syringes and cartridges for clinical and commercial supply. Argonaut expects to have fully validated the facility and all equipment in 2025.